218
Participants
Start Date
June 30, 2007
Primary Completion Date
May 31, 2008
Study Completion Date
October 31, 2008
Placebo
Placebo vaginal suppository containing 0.0% (0 mg) DHEA; daily dosing with one suppository for 12 weeks.
DHEA (0.25%)
Vaginal suppository containing 0.25% (3.25 mg) DHEA; daily dosing with one suppository for 12 weeks.
DHEA (0.5%)
Vaginal suppository containing 0.5% (6.5 mg) DHEA; daily dosing with one suppository for 12 weeks.
DHEA (1.0%)
Vaginal suppository containing 1.0% (13 mg) DHEA; daily dosing with one suppository for 12 weeks.
EndoCeutics site # 03, Norfolk
EndoCeutics site # 05, Cleveland
EndoCeutics site # 10, Montreal
EndoCeutics site # 09, Montreal
EndoCeutics site # 08, Shawinigan
EndoCeutics site # 11, Sherbrooke
EndoCeutics site # 02, Québec
EndoCeutics site # 01, Québec
Lead Sponsor
EndoCeutics Inc.
INDUSTRY